Minton J P, Chevinsky A
Department of Surgery, Ohio State University College of Medicine, Columbus 43210.
Semin Surg Oncol. 1989;5(6):426-35. doi: 10.1002/ssu.2980050609.
Tumor markers presently in use generally meet only one or two of the criteria for the ideal marker, which are: tumor specificity, correlation with tumor bulk and stage of the disease, decrease to normal after successful treatment, and rise prior to clinical manifestations of recurrence. In addition, virtually all are elevated in some benign conditions. Currently their greatest usefulness is for confirmation of clinical suspicion and for monitoring known disease. Some tumor markers which are not effective as screening tests can be used to evaluate the patient's response to therapy. The discovery of oncogenes holds great promise for a new generation of tumor markers. Major breakthroughs in the fields of molecular biology and tumor immunology seem imminent with eventual application possibly in the treatment of cancer.
目前使用的肿瘤标志物通常仅满足理想标志物的一两条标准,这些标准包括:肿瘤特异性、与肿瘤大小和疾病分期相关、成功治疗后降至正常水平以及在复发临床表现出现之前升高。此外,几乎所有肿瘤标志物在某些良性疾病中也会升高。目前它们最大的用途是确认临床怀疑和监测已知疾病。一些作为筛查试验无效的肿瘤标志物可用于评估患者对治疗的反应。癌基因的发现为新一代肿瘤标志物带来了巨大希望。分子生物学和肿瘤免疫学领域的重大突破似乎即将到来,最终可能应用于癌症治疗。